A phase I study involving IL-21 monotherapy for metastatic melanoma or renal cell carcinoma reported that monotherapy was well tolerated and exhibited anti-tumour activity in some patients (Davis et al, 2007; Thompson et al, 2008), thereby suggesting that IL-21 may have an anti-tumour effect as a monotherapy. This evidence concerns the gene IL21 and metastatic melanoma.